Hoechst Marion Roussel Anzemet launch awaits FDA labeling negotiations; dolasetron approved Sept. 11.
HMR ANZEMET LAUNCH AWAITS FDA LABELING NEGOTIATIONS with Hoechst Marion Roussel following the Sept. 11 approval of the anti-emetic agent. Anzemet (dolasetron) 50 and 100 mg tablets were approved for prevention of chemotherapy-induced nausea and vomiting and prevention of postoperative nausea and vomiting. Anzemet 20 mg/mL I.V. gained an additional approval for the treatment of postoperative nausea and vomiting. Advertising for Anzemet will be handled by NCI in New York.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth